Luca Benatti, Ph.D.

Director, Newron Pharmaceuticals S.p.A, Intercept Pharmaceutical, and CasRevolution

Luca Benatti, Ph.D., has served as a member of Quince’s Board of Directors since October 2023.

Dr. Benatti has more than 30 years of experience in the pharmaceutical and biotechnology industries. Most recently, he served as Chief Executive Officer and Director of EryDel S.p.A., a private biotechnology company focused on rare diseases, prior to its acquisition by Quince Therapeutics in October 2023. From 1998 to May 2012, Dr. Benatti was Chief Executive Officer and Co-founder of Newron Pharmaceuticals S.p.A., a publicly traded biopharmaceutical company. Under his leadership, Newron developed a pipeline of innovative therapies, including Xadago, which was approved worldwide for the treatment of Parkinson’s disease. From 1985 to 1998, Dr. Benatti held various research and development positions at Pharmacia & Upjohn and its predecessor companies. He has authored several scientific publications and holds a number of patents.

Dr. Benatti currently serves as a director of Newron Pharmaceuticals S.p.A (SIX: NWRN), Intercept Pharmaceutical (ICPT: Nasdaq) and CasRevolution. He also serves as Chairman of Italian Angels for Biotech and of the Scientific Advisory Board of Gain Therapeutics, in addition to being a member of the Advisory Board of the Sofinnova Telethon Fund, as well as a member of the Development Advisory Board of Zambon S.p.A.

View Our Board